GU Cancers 2026 | First results of CBM588 with nivolumab and ipilimumab in mRCC
Miguel Zugman, MD, Albert Einstein Israelite Hospital, Sao Paolo, Brazil, discusses initial results from a dose-escalation study (NCT06399419) of CBM588 (Clostridium butyricum MIYAIRI 588) combined with nivolumab and ipilimumab in treatment-naïve metastatic renal cell carcinoma (mRCC). The study demonstrated no dose-limiting toxicities at any dose level, with no dose-dependent increase in immune-related adverse events. Translational analyses revealed dose-dependent modulation of gut microbiome composition and changes in biomarker levels associated with treatment response. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
